Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Responses to avapritinib in patients with advanced systemic mastocytosis

Tracy George • 12 Jun 2022
EHA 2022
Myeloproliferative Neoplasms Rare Diseases Systemic Mastocytosis Avapritinib

Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT, discusses the efficacy of avapritinib in patients with advanced systemic mastocytosis. In this video, Dr George highlights the decrease in mast cell burden and hypercellularity in the bone marrow and the promise of this agent for the treatment of systemic mastocytosis. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultant, cogent blueprint

More from Tracy George

1:44
Emerging novel agents for the treatment of mastocytosis
Tracy George • 12 Jun 2022
1:49
Unmet needs and challenges in mastocytosis
Tracy George • 12 Jun 2022
0:37
Emerging targeted agents in the field of mastocytosis
Tracy George • 1 Apr 2021
3:37
Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib
Tracy George • 1 Apr 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals